BRD4 and breast cancer: These in vivo data support our findings in cell culture experiments and further strengthen the hypotheses that the FOXO3a-BRD4-CDK6 axis is critical for conferring drug resistance to AKTi and inhibitors of FOXO3a-BRD4 and CDK6 can sensitize the growth suppressive effects mediated by AKTi in luminal breast cancer.